SMS Lifesciences India Limited , a prominent player in the pharmaceutical sector, has announced a significant corporate rebranding. The company has officially changed its name to Haleos Labs Limited, marking a new chapter in its corporate identity.

Key Details of the Name Change

Approval Process

The name change follows a comprehensive approval process, ensuring compliance with all regulatory requirements:

1. Board Approval
2. Shareholders' Approval
3. Ministry of Corporate Affairs (MCA) Approval
4. National Stock Exchange (NSE) Approval
5. Bombay Stock Exchange (BSE) Approval

Impact on Company Operations

It's important to note that this rebranding initiative is primarily a change in corporate identity. The company has clarified that:

• The legal status of the company remains unaltered
• The Corporate Identification Number (CIN) remains unchanged
• There is no impact on the company's day-to-day operations

Investor Implications

For investors and stakeholders, the primary change will be in the company's representation on stock exchanges. The new trading symbol 'HALEOSLABS' will replace the previous 'SMSLIFE' on both the National Stock Exchange and the Bombay Stock Exchange.

This corporate action reflects the company's evolution and potentially its future strategic direction. While the core business operations remain unchanged, the new brand identity might signal the company's aspirations or a shift in its market positioning.

Investors and market participants should take note of this change to avoid any confusion in their trading or investment activities. It's advisable to update any automated trading systems or watchlists to reflect the new trading symbol.

As with any significant corporate change, stakeholders should monitor for any subsequent announcements or changes that might follow this rebranding exercise.

SMS Lifesciences , now known as Haleos Labs Limited, has reported its financial results for the second quarter of fiscal year 2026, showing a decline in both revenue and profit compared to the same period last year.

Key Financial Highlights

• Net Profit: Rs 497.77 lakhs for Q2 FY2026, down 17.15% from Rs 600.83 lakhs in Q2 FY2025
• Revenue from Operations: Rs 7,784.38 lakhs, a slight decrease of 0.83% from Rs 7,849.62 lakhs year-over-year
• Basic Earnings Per Share: Rs 16.46, compared to Rs 19.87 in the corresponding quarter of the previous year

Half-Year Performance

For the first half of FY2026, Haleos Labs reported:

• Net Profit: Rs 1,013.54 lakhs, down 18.71% from Rs 1,246.82 lakhs in H1 FY2025
• Revenue: Rs 15,688.63 lakhs, a decrease of 4.96% from Rs 16,506.68 lakhs in the previous year

Financial Position

The company's balance sheet as of September 30, 2025, shows:

Business Overview

Haleos Labs Limited, which officially changed its name from SMS Lifesciences India Limited on August 21, 2025, is a pharmaceutical company specializing in the manufacture of Active Pharmaceutical Ingredients (APIs) and their intermediates.

Management Commentary

The financial statements were approved by the Board of Directors at their meeting held on November 10, 2025, after being reviewed and recommended by the Audit Committee.

Auditor's Review

The statutory auditors, CA Rambabu & Co., have carried out a limited review of the financial results for the quarter and half-year ended September 30, 2025, and have expressed an unmodified opinion.

Conclusion

Haleos Labs Limited has experienced a decline in both revenue and profit for Q2 FY2026 compared to the same period last year, while maintaining a strong balance sheet. The recent change in the company's name may indicate a new strategic direction, although no specific details have been provided regarding future plans or the reasons behind the current financial performance.